(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.18%) $79.09
(-1.03%) $2.01
(0.04%) $2 310.50
(0.19%) $26.88
(0.29%) $965.40
(-0.05%) $0.932
(-0.09%) $10.98
(-0.13%) $0.797
(1.51%) $92.50
Live Chart Being Loaded With Signals
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform...
Stats | |
---|---|
Šios dienos apimtis | 756.00 |
Vidutinė apimtis | 0.00 |
Rinkos kapitalizacija | 10 065.00 |
EPS | $-0.150 ( 2016-05-12 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2016-03-16 | Mitchell Daniel J | Sell | 8 862 | Common Stock |
2016-03-17 | Mitchell Daniel J | Sell | 12 468 | Common Stock |
2016-03-16 | Mitchell Daniel J | Sell | 112 | Common Stock |
2016-03-17 | Mitchell Daniel J | Sell | 158 | Common Stock |
2016-03-11 | Mitchell Daniel J | Sell | 76 662 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 99 transactions |
Buy: 1 518 952 | Sell: 29 605 418 |
Tūris Koreliacija
GlobeImmune, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
GlobeImmune, Inc. Koreliacija - Valiuta/Žaliavos
GlobeImmune, Inc. Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $0 |
FY | 2015 |
Pajamos: | $6.46M |
Bruto pelnas: | $6.46M (100.00 %) |
EPS: | $-0.480 |
FY | 2014 |
Pajamos: | $5.97M |
Bruto pelnas: | $5.97M (100.00 %) |
EPS: | $-5.58 |
Financial Reports:
No articles found.
GlobeImmune, Inc.
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.